Teva Pharmaceutical Industries and Sanofi announced positive efficacy data from the RELIEVE UCCD Phase 3 trial evaluating duvakitug, an investigational oral treatment for inflammatory bowel disease. The study demonstrated sustained clinical benefit over a 44-week treatment period, with 58% of ulcerative colitis patients and 55% of Crohn's disease patients meeting primary efficacy endpoints at the 900 mg dosage level.
The trial results represent a significant milestone in the development of duvakitug, which targets a novel mechanism of action for IBD management. The durability of response across both indications suggests potential clinical utility in addressing the chronic nature of inflammatory bowel conditions, where maintaining long-term remission remains a key therapeutic objective.
Market reaction to the announcement was positive, with Teva shares advancing 2.85% in premarket trading. The companies plan to advance duvakitug through regulatory discussions based on these trial outcomes. Additional data from the RELIEVE UCCD study are expected to be presented at upcoming medical conferences.